Seelos Therapeutics Provides Update On Top-Line Results From Its Amyotrophic Lateral Sclerosis Study With SLS-005
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics, Inc. (NASDAQ:SEEL) provided an update on its Phase 2/3 HEALEY ALS Platform trial for SLS-005 in ALS treatment. The study didn't meet primary and secondary endpoints but showed a potential efficacy signal in a pre-specified subgroup. SLS-005 demonstrated a 22% improvement in ALSFRS-R slope and a 25% slowing in SVC decline in this subgroup. Seelos plans to request an FDA meeting for next steps and continue partner discussions. SLS-005 was well-tolerated, with an imbalance in deaths deemed unrelated to the drug.
March 19, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seelos Therapeutics' ALS study for SLS-005 showed potential efficacy in a subgroup, despite not meeting main endpoints. Plans for FDA discussion and further analysis.
The news about the potential efficacy signal in a subgroup for SLS-005, despite not meeting the primary and secondary endpoints, could be seen positively by investors as it indicates a path forward for the drug's development. The company's intention to discuss next steps with the FDA and continue partner discussions could be viewed as a proactive approach to advancing SLS-005's development, potentially leading to a positive short-term impact on SEEL's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100